

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

NCT05909761

Status RECRUITING
Sponsor Amgen
Enrollment 60 participants

Key Eligibility Criteria

Inclusion (3)

- Provide informed consent
- Are a female of reproductive potential with a confirmed or suspected diagnosis of NMOSD
- Have been exposed to UPLIZNA during pregnancy as defined by receipt of any dose during pregnancy or within 6 months preceding conception

Locations (1 total)

University of Colorado Denver, Aurora, Colorado, United States